Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of GFT505 80 mg in type 2 diabetes mellitus
2010-021986-60Phase 2Completed
- Sponsor
- Genfit
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing GFT505 80 mg with Placebo (2 arms). Primary endpoint: Change in HbA1c at 12 weeks vs placebo. Started Oct 2010; status: completed.
02
Drugs
elafibranor
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-021986-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021986-60.